CyDex Pharmaceuticals, Inc. today announced the extension of its relationship with Hovione SA as the company’s exclusive supplier of Captisol® for an additional five years.
“The extension of our relationship with Hovione through 2019 provides assurance for current and future CyDex strategic partners that they will continue to have uninterrupted access to high-quality Captisol®,” said CyDex President and Chief Executive Officer Theron E. Odlaug. “This arrangement is an important step forward as we develop and commercialize pharmaceuticals and therapies using our differentiated cyclodextrin technology.”
Today’s announcement is in conjunction with Odlaug’s presentation at Hovione’s 50th anniversary commemoration at Hovione’s headquarters in Loures, Portugal. “We are pleased to be extending one of CyDex’s most important business relationships,” he said. “Hovione’s ability to consistently meet the highest standards in pharmaceutical manufacturing is evidenced by their 50 years of business excellence. On behalf of the entire CyDex team, I congratulate our partners at Hovione for achieving this milestone.”